Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging

Parkinsonism and Related Disorders

Volumn 12, Issue 4, 2006, Pages 228-238

  Phinney, Amie L ^a   Andringa, Gerda ^a   Bol, John G J M ^a   Wolters, Erik Ch ^a   Muiswinkel, Freek L van ^b   Dam, Anne Marie W van ^a   Drukarch, Benjamin ^a  

^a Institute for Clinical and Experimental Neurosciences ICEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Neurodegeneration; Parkinson's disease; Pesticide; Stereology; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

ALPHA SYNUCLEIN; NEUROTRANSMITTER; ROTENONE; TYROSINE 3 MONOOXYGENASE;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL DENSITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GLIA CELL; MALE; MICROGLIA; NERVE ENDING; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; SUBSTANTIA NIGRA;

AGING; ALPHA-SYNUCLEIN; ANIMALS; ASTROCYTES; CELL COUNT; DOPAMINE; IMMUNOHISTOCHEMISTRY; INSECTICIDES; MALE; MICROGLIA; NEOSTRIATUM; NEURONS; NEUROTRANSMITTER AGENTS; PRESYNAPTIC TERMINALS; RATS; RATS, INBRED LEW; ROTENONE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 33646689597     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2005.12.002     Document Type: Article

References (77)

1. Jenner P. Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci 24 5 (2001) 245-247
2. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 6 (2003) 889-909
3. Hald A., and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp Neurol 193 2 (2005) 279-290
4. Le Couteur D.G., Muller M., Yang M.C., Mellick G.D., and McLean A.J. Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease. Rev Environ Health 17 1 (2002) 51-64
5. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1 8649 (1989) 1269
6. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54 3 (1990) 823-827
7. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., and Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163 3 (1989) 1450-1455
8. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., Bennett Jr JP., Davis R.E., and Parker Jr W.D. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40 4 (1996) 663-671
9. Greenamyre J.T., MacKenzie G., Peng T.I., and Stephans S.E. Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp 66 (1999) 85-97
10. Checkoway H., and Nelson L.M. Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology 10 3 (1999) 327-336
11. Hertzman C., Wiens M., Snow B., Kelly S., and Calne D. A case-control study of Parkinson's disease in a horticultural region of British Columbia. Mov Disord 9 1 (1994) 69-75
12. Ritz B., and Yu F. Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int J Epidemiol 29 2 (2000) 323-329
13. Wang F., Semchuk K.M., and Love E.J. An assessment of the usefulness of demographic data provided by surrogate respondents in a case-control study of Parkinson's disease. J Clin Epidemiol 45 11 (1992) 1219-1227
14. Semchuk K.M., Love E.J., and Lee R.G. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 42 7 (1992) 1328-1335
15. Gorell J.M., Peterson E.L., Rybicki B.A., and Johnson C.C. Multiple risk factors for Parkinson's disease. J Neurol Sci 217 2 (2004) 169-174
16. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., and Richardson R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50 5 (1998) 1346-1350
17. Perier C., Bove J., Vila M., and Przedborski S. The rotenone model of Parkinson's disease. Trends Neurosci 26 7 (2003) 345-346
18. Greenamyre J.T., Betarbet R., and Sherer T.B. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord 9 Suppl. 2 (2003) S59-S64
19. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23 34 (2003) 10756-10764
20. Shamoto-Nagai M., Maruyama W., Kato Y., Isobe K., Tanaka M., Naoi M., and Osawa T. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res 74 4 (2003) 589-597
21. Alam M., and Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136 1 (2002) 317-324
22. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 12 (2000) 1301-1306
23. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179 1 (2003) 9-16
24. Ferrante R.J., Schulz J.B., Kowall N.W., and Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 753 1 (1997) 157-162
25. Hoglinger G.U., Feger J., Prigent A., Michel P.P., Parain K., Champy P., Ruberg M., Oertel W.H., and Hirsch E.C. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 84 3 (2003) 491-502
26. Zhu C., Vourc'h P., Fernagut P.O., Fleming S.M., Lacan S., Dicarlo C.D., Seaman R.L., and Chesselet M.F. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J Comp Neurol 478 4 (2004) 418
27. Fleming S.M., Zhu C., Fernagut P.O., Mehta A., DiCarlo C.D., Seaman R.L., and Chesselet M.F. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 187 2 (2004) 418-429
28. Lapointe N., St-Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., and Cicchetti F. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 18 6 (2004) 717-719
29. Calne D.B., and Langston J.W. Aetiology of Parkinson's disease. Lancet 2 8365-66 (1983) 1457-1459
30. Barbeau A. Etiology of Parkinson's disease: a research strategy. Can J Neurol Sci 11 1 (1984) 24-28
31. Irwin I., Finnegan K.T., Delanney L.E., Di Monte D., and Langston J.W. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Res 572 1-2 (1992) 224-231
32. Tatton W.G., Greenwood C.E., Seniuk N.A., and Salo P.T. Interactions between MPTP-induced and age-related neuronal death in a murine model of Parkinson's disease. Can J Neurol Sci 19 1 (1992) 124-133
33. Irwin I., DeLanney L.E., and Langston J.W. MPTP and aging. Studies in the C57BL/6 mouse. Adv Neurol 60 (1993) 197-206
34. Sugama S., Yang L., Cho B.P., DeGiorgio L.A., Lorenzl S., Albers D.S., Beal M.F., Volpe B.T., and Joh T.H. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 964 2 (2003) 288-294
35. Date I., Felten D.L., and Felten S.Y. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res 519 1-2 (1990) 266-276
36. Thiruchelvam M., McCormack A., Richfield E.K., Baggs R.B., Tank A.W., Di Monte D.A., and CorySlechta D.A. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci 18 3 (2003) 589-600
37. Cass W.A., Harned M.E., and Bailey S.L. Enhanced effects of 6-hydroxydopamine on evoked overflow of striatal dopamine in aged rats. Brain Res 938 1-2 (2002) 29-37
38. Pasinetti G.M., Hassler M., Stone D., and Finch C.E. Glial gene expression during aging in rat striatum and in long-term responses to 6-OHDA lesions. Synapse 31 4 (1999) 278-284
39. Yurek D.M., and Fletcher-Turner A. Lesion-induced increase of BDNF is greater in the striatum of young versus old rat brain. Exp Neurol 161 1 (2000) 392-396
40. Yurek D.M., and Fletcher-Turner A. Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion. Brain Res 891 1-2 (2001) 228-235
41. Genova M.L., Bovina C., Marchetti M., Pallotti F., Tietz C., Biagini G., Pugnaloni A., Viticchi C., Gorini A., Villa R.F., and Lenaz G. Decrease of rotenone inhibition is a sensitive parameter of complex I damage in brain non-synaptic mitochondria of aged rats. FEBS Lett 410 2-3 (1997) 467-469
42. Lenaz G., Bovina C., Castelluccio C., Fato R., Formiggini G., Genova M.L., Marchetti M., Pich M.M., Pallotti F., Parenti Castelli G., and Biagini G. Mitochondrial complex I defects in aging. Mol Cell Biochem 174 1-2 (1997) 329-333
43. Merlo Pich M., Bovina C., Formiggini G., Cometti G.G., Ghelli A., Parenti Castelli G., Genova M.L., Marchetti M., Semeraro S., and Lenaz G. Inhibitor sensitivity of respiratory complex I in human platelets: a possible biomarker of ageing. FEBS Lett 380 1-2 (1996) 176-178
44. Felzien L.K., McDonald J.T., Gleason S.M., Berman N.E., and Klein R.M. Increased chemokine gene expression during aging in the murine brain. Brain Res 890 1 (2001) 137-146
45. Overmyer M., Helisalmi S., Soininen H., Laakso M., Riekkinen P., and Alafuzoff Sr. I. Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue. Acta Neuropathol Berl 97 4 (1999) 383-392
46. Linnemann D., and Skarsfelt T. Regional changes in expression of NCAM, GFAP, and S100 in aging rat brain. Neurobiol Aging 15 5 (1994) 651-655
47. Gao H.M., Hong J.S., Zhang W., and Liu B. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci 23 4 (2003) 1228-1236
48. Gao H.M., Liu B., and Hong J.S. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 23 15 (2003) 6181-6187
49. Van Muiswinkel F.L., Jongenelen C.A., Schepens H.T., Stoof J.C., and Drukarch B. Effects of chronic activation of dopamine D-2 receptors in cultures of rat fetal dopaminergic neurons: indications for alterations in functional activity. Brain Res Dev Brain Res 85 1 (1995) 128-136
50. Guntern R., Bouras C., Hof P.R., and Vallet P.G. An improved thioflavine S method for staining neurofibrillary tangles and senile plaques in Alzheimer's disease. Experientia 48 1 (1992) 8-10
51. Van De Witte S.V., Groenewegen H.J., and Voorn P. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons. Synapse 43 1 (2002) 1-11
52. West M.J. New stereological methods for counting neurons. Neurobiol Aging 14 4 (1993) 275-285
53. West M.J., Slomianka L., and Gundersen H.J. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231 4 (1991) 482-497
54. Finkelstein D.I., Stanic D., Parish C.L., Tomas D., Dickson K., and Horne M.K. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97 1 (2000) 99-112
55. Gundersen H.J., Jensen E.B., Kieu K., and Nielsen J. The efficiency of systematic sampling in stereology-reconsidered. J Microsc 3 Pt 3 (1999) 199-211
56. Paxino G., and Watson C. The rat brain in stereotaxic coordinates (1982), Academic Press, London
57. Van Muiswinkel F.L., Bol J.G., Ruijter J.M., Stoof J.C., Drukarch B., and Steinbusch H.W. Repeated administration of a selective dopamine D2 receptor agonist to 6-OHDA-lesioned rats does not affect the survival and outgrowth of intrastriatal fetal mesencephalic grafts. Exp Brain Res 107 1 (1995) 52-58
58. Joel D., and Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96 3 (2000) 451-474
59. Date I., Felten S.Y., Olschowka J.A., and Felten D.L. Limited recovery of striatal dopaminergic fibers by adrenal medullary grafts in MPTP-treated aging mice. Exp Neurol 107 3 (1990) 197-207
60. Baldo B.A., Sadeghian K., Basso A.M., and Kelley A.E. Effects of selective dopamine D1 or D2 receptor blockade within nucleus accumbens subregions on ingestive behavior and associated motor activity. Behav Brain Res 137 1-2 (2002) 165-177
61. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res (2004)
62. Blanchard V., Chritin M., Vyas S., Savasta M., Feuerstein C., Agid Y., Javoy-Agid F., and Raisman-Vozari R. Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain. J Neurochem 64 4 (1995) 1669-1679
63. Blanchard V., Anglade P., Dziewczapolski G., Savasta M., Agid Y., and Raisman-Vozari R. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res 709 2 (1996) 319-325
64. Onn S.P., Berger T.W., Stricker E.M., and Zigmond M.J. Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: histochemical and neurochemical analysis. Brain Res 376 1 (1986) 8-19
65. Bezard E., Jaber M., Gonon F., Boireau A., Bloch B., and Gross C.E. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur J Neurosci 12 8 (2000) 2892-2900
66. Ricaurte G.A., DeLanney L.E., Irwin I., and Langston J.W. Older dopaminergic neurons do not recover from the effects of MPTP. Neuropharmacology 26 1 (1987) 97-99
67. Date I., Notter M.F., Felten S.Y., and Felten D.L. MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF). Brain Res 526 1 (1990) 156-160
68. Anderson C.P., Rozovsky I., Stone D.J., Song Y., Lopez L.M., and Finch C.E. Aging and increased hypothalamic glial fibrillary acid protein (GFAP) mRNA in F344 female rats. Dissociation of GFAP inducibility from the luteinizing hormone surge. Neuroendocrinology 76 2 (2002) 121-130
69. Streit W.J., Sammons N.W., Kuhns A.J., and Sparks D.L. Dystrophic microglia in the aging human brain. Glia 45 2 (2004) 208-212
70. Rozovsky I., Finch C.E., and Morgan T.E. Age-related activation of microglia and astrocytes: in vitro studies show persistent phenotypes of aging, increased proliferation, and resistance to down-regulation. Neurobiol Aging 19 1 (1998) 97-103
71. Schwartz M. Macrophages and microglia in central nervous system injury: are they helpful or harmful?. J Cereb Blood Flow Metab 23 4 (2003) 385-394
72. Gao H.M., Hong J.S., Zhang W., and Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22 3 (2002) 782-790
73. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim Biophys Acta 1364 2 (1998) 222-235
74. Junqueira V.B., Barros S.B., Chan S.S., Rodrigues L., Giavarotti L., Abud R.L., and LDeucher G.P. Aging and oxidative stress. Mol Aspects Med 25 1-2 (2004) 5-16
75. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., and Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22 16 (2002) 7006-7015
76. Yang M.C., McLean A.J., and Le Couteur D.G. Age-related alteration in hepatic disposition of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and pesticides. Pharmacol Toxicol 90 4 (2002) 203-207
77. Mooradian A.D. Effect of aging on the blood-brain barrier. Neurobiol Aging 9 1 (1988) 31-39